Phase II study of irinotecan (I) and cetuximab (C) on an every 2 week schedule, as second line therapy in patients (pts) with advanced colo-rectal cancer (CRC)

Autor:	Marwan Fakih, R. A. Pinkerton, Barry C. Lembersky, Ramesh K. Ramanathan, Nathan Bahary, S. Lancaster, Amy Schmotzer, Theodore L. Crandall, Alok A. Khorana, Smitha S. Krishnamurthi
Rok vydání:	2008
Předmět:	Oncology Cancer Research medicine.medical_specialty Second-line therapy Cetuximab Bevacizumab business.industry Phases of clinical research Colo-rectal cancer Surgery Oxaliplatin Irinotecan stomatognathic diseases Regimen Internal medicine medicine business medicine.drug
Zdroj:	Journal of Clinical Oncology. 26:15050-15050
ISSN:	1527-7755 0732-183X
Popis:	15050 Background: I + C is a standard second line regimen for pts treated with 5-flurouracil, oxaliplatin and bevacizumab in the US. Second line therapy with I + C results in a response rate (RR) o...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fee6b12dc8f7ef4404aded54409269c4 https://doi.org/10.1200/jco.2008.26.15_suppl.15050 Zobrazit plný text záznamu